- Pembrolitzumab in the treatment of NSCLC2017 | Publication without faculty affiliation
- Strategies for current NSCLC treatment2020 | Publication without faculty affiliation
- Osimertinib and its role in first-line NSCLC treatment2020 | Publication without faculty affiliation
- First-line immunotherapy in NSCLC - what brought 20182018 | Faculty of Medicine in Pilsen
- What approach to ALK-positive NSCLC?2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy2013 | Faculty of Medicine in Pilsen
- Gemcitabine in non-small cell lung cancer (NSCLC)2000 | Third Faculty of Medicine
- New methodology of TMB assessment from tissue and liquid biopsy in NSCLC2022 | First Faculty of Medicine
- Erlotinib in the treatment of advanced squamous cell NSCLC2013 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- EGFR mutations in patients with advanced NSCLC2012 | Faculty of Medicine in Pilsen
- Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC2013 | Faculty of Medicine in Pilsen
- Personalized cancer treatment of patients with advanced-stage NSCLC2015 | Faculty of Medicine in Pilsen, Faculty of Science
- KRAS (G12S) mutation in a patient with NSCLC treated with erlotinib – a case report2013 | Faculty of Medicine in Pilsen
- Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment2021 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design2021 | First Faculty of Medicine
- The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy2016 | Faculty of Medicine in Pilsen
- The role of durvalumab in the treatment of stage III NSCLC2020 | First Faculty of Medicine
- Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC2009 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Case report of a patient with generalized NSCLC with high PD-L1 expression treated with pembrolizumab2020 | Publication without faculty affiliation
- The current standard of NSCLC pathological examination in the Czech Republic2022 | Faculty of Medicine in Hradec Kr álové
- The new moleculary targeted drug for the treatment of non small cell lung cancer (NSCLC)2011 | Faculty of Medicine in Pilsen
- Longer survival in patients with NSCLC thanks to the combination of chemotherapy, immunotherapy and targeted therapy in the first line palliative treatment - results of the IMpower150 study2020 | Third Faculty of Medicine
- Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib2014 | Faculty of Medicine in Pilsen
- Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)2022 | First Faculty of Medicine
- Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice2013 | Faculty of Medicine in Pilsen
- Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab plus Chemotherapy2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- The use of tumor markers in predicting reccurence of non-small cell lung cancer (NSCLC) after radical surgery2007 | Central Library of Charles University
- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine